Use of recombinant human osteogenic protein-1 for the repair of subchondral defects in articular cartilage in goats.
The objective of this pilot study was to examine in vivo the potential of recombinant human osteogenic protein-1 (rhOP-1, also called bone morphogenetic protein-7, BMP-7) for treatment of subchondral lesions by induction of new hyaline cartilage formation. Subchondral left knee defects in 17 mature goats were treated with fresh coagulated blood mixed with (1) rhOP-1 combined with collagen (OP-1 device, 400 microgram/mL); (2) rhOP-1 alone (OP-1 peptide, 200 microgram/mL); (3) OP-1 device with small particles of autologous ear perichondrium; (4) OP-1 peptide with small particles of autologous ear perichondrium; or (5) autologous ear perichondrium alone (controls). rhOP-1 was combined with either collagen (OP-1 device) or not (OP-1 peptide). The defects were closed with a periosteal flap. The formation of cartilage tissue was studied by histologic and biochemical evaluation at 1, 2, and 4 months after implantation. One and 2 months after implantation there were no obvious differences between control and rhOP-1-treated defects. Four months after implantation, only one out of three controls (without rhOP-1) showed beginning signs of cartilage formation while all four rhOP-1-treated defects were completely or partly filled with cartilage. A significant linear relationship was found between rhOP-1 concentration and the total amount of aggrecan in the defects. These results suggest that implantation of rhOP-1 promotes cartilage formation in subchondral defects in goats at 4 months after implantation. Therefore, rhOP-1 could be a novel factor for regeneration of cartilage in articular cartilage defects.
Louwerse
R T
RT
Department of Orthopaedic Surgery, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands.
Heyligers
I C
IC
Klein-Nulend
J
J
Sugihara
S
S
van Kampen
G P
GP
Semeins
C M
CM
Goei
S W
SW
de Koning
M H
MH
Wuisman
P I
PI
Burger
E H
EH
D000818:Animals; D001672:Biocompatible Materials; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000187:drug effects / Q000502:physiology*; D002358:Cartilage, Articular / Q000187:drug effects / Q000473:pathology*; D004425:Ear Cartilage / Q000637:transplantation*; D006041:Goats; D006801:Humans; D007596:Joints / Q000187:drug effects / Q000473:pathology*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D016212:Transforming Growth Factor beta; D014182:Transplantation, Autologous
C525819:BMP7 protein, human; D001672:Biocompatible Materials; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta